Vertex reported positive Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease across two patient cohorts.
Treatment reduced protein in urine in patients with modest proteinuria, supporting potential use beyond the earlier focal segmental glomerulosclerosis population.
Patients with type 2 diabetes saw a smaller improvement, suggesting a more variable response in that subgroup.
Safety profile was generally favorable, with no drug-related serious adverse events reported.
Enrollment finished in the Phase 2/3 AMPLITUDE trial, with interim results expected in early 2027.
VRTX•
